Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol

J Heart Lung Transplant. 2005 Apr;24(4):501-3. doi: 10.1016/j.healun.2004.02.004.

Abstract

We report the first case in the world literature of a patient with an atrial septal defect, severe pulmonary hypertension, and equalization of pulmonary and systemic pressures, who underwent successful closure of an ASD following prolonged therapy with the intravenous vasodilator epoprostenol. Judicious use of continuous prostacyclin in apparently inoperable patients with congenital heart disease may be associated with significant reversal of pulmonary hypertension, and conversion to an operable state.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antihypertensive Agents / administration & dosage*
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Cardiac Catheterization
  • Cardiac Output / physiology
  • Cardiac Surgical Procedures*
  • Echocardiography, Transesophageal
  • Epoprostenol / administration & dosage*
  • Female
  • Follow-Up Studies
  • Heart Septal Defects, Atrial / complications
  • Heart Septal Defects, Atrial / diagnosis
  • Heart Septal Defects, Atrial / surgery*
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / physiopathology
  • Infusions, Intravenous
  • Perioperative Care*
  • Pulmonary Wedge Pressure / drug effects
  • Pulmonary Wedge Pressure / physiology
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Epoprostenol